Submit
an article to
an article to
-
Font Size:
-
Print
- TweetThis
Rumors of a buyout sent Biogen Idec (BIIB) shares up about $13 to over $82 per share.
I first recommended BIIB last year at $44.6 based on the potential success of Tysabri in treating MS (link to that article). As of Tuesday's price, the stock is up 84% and I am recommending to sell and to take any profits as I believe a buyout is far from certain and any changes to these speculations will send the stock back down to $70.
Buying at these levels is definitely not recommended since the price is way too expensive based on fundamentals.
BIIB 1-yr chart:
Disclosure: The author does not have a position in BIIB at this time.
Related Articles
|
Comments
1
Comment 1 out of 1
You are viewing the latest 20 comments
-
- borisb:
- Comments (361)
- • Instablog (1)
- • StockTalk (3)
good call. now what?2007 Nov 22 08:27 PM | Link | Reply
Register or Login to rate comments »
Viewing Comment 1 out of 1





















